MedTrace Logo

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

NCT03694262 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-13

Study results available
· View outcomes & findings →

Summary

To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.

Conditions

Interventions

DRUG

Rucaparib

Rucaparib 600mg orally twice daily by continuous dosing

DRUG

Bevacizumab

15mg/kg IV on day 1 of every cycle

DRUG

Atezolizumab

1,200mg IV on day 1 of every cycle

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Clovis Oncology, Inc.

    collaborator INDUSTRY

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • William Bradley, MD · Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-19
Primary Completion
2023-03-30
Completion
2026-03-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03694262 on ClinicalTrials.gov